ADVM Valuation

Adverum Biotechnologies Inc

Add to Watchlist

Advanced Chart

2.860

0(0.000%)1D

Overview
Forecast
Valuation
Earnings

ADVM Relative Valuation

ADVM's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ADVM is overvalued; if below, it's undervalued.

Historical Valuation

Adverum Biotechnologies Inc (ADVM) is now in the Fair zone, suggesting that its current forward PS ratio of 4.59 is considered Fairly compared with the five-year average of -6.11. The fair price of Adverum Biotechnologies Inc (ADVM) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：2.86

Fair

-0.85

Trailing

Forward

-0.50

EV/EBITDA

Adverum Biotechnologies Inc. (ADVM) has a current EV/EBITDA of -0.50. The 5-year average EV/EBITDA is -1.01. The thresholds are as follows: Strongly Undervalued below -5.51, Undervalued between -5.51 and -3.26, Fairly Valued between 1.24 and -3.26, Overvalued between 1.24 and 3.49, and Strongly Overvalued above 3.49. The current Forward EV/EBITDA of -0.50 falls within the Historic Trend Line -Fairly Valued range.

-0.54

EV/EBIT

Adverum Biotechnologies Inc. (ADVM) has a current EV/EBIT of -0.54. The 5-year average EV/EBIT is -0.99. The thresholds are as follows: Strongly Undervalued below -5.28, Undervalued between -5.28 and -3.14, Fairly Valued between 1.15 and -3.14, Overvalued between 1.15 and 3.29, and Strongly Overvalued above 3.29. The current Forward EV/EBIT of -0.54 falls within the Historic Trend Line -Fairly Valued range.

4.59

Adverum Biotechnologies Inc. (ADVM) has a current PS of 4.59. The 5-year average PS is 474.45. The thresholds are as follows: Strongly Undervalued below -1573.81, Undervalued between -1573.81 and -549.68, Fairly Valued between 1498.58 and -549.68, Overvalued between 1498.58 and 2522.71, and Strongly Overvalued above 2522.71. The current Forward PS of 4.59 falls within the Historic Trend Line -Fairly Valued range.

-0.30

P/OCF

Adverum Biotechnologies Inc. (ADVM) has a current P/OCF of -0.30. The 5-year average P/OCF is -2.59. The thresholds are as follows: Strongly Undervalued below -9.61, Undervalued between -9.61 and -6.10, Fairly Valued between 0.92 and -6.10, Overvalued between 0.92 and 4.43, and Strongly Overvalued above 4.43. The current Forward P/OCF of -0.30 falls within the Historic Trend Line -Fairly Valued range.

-0.30

P/FCF

Adverum Biotechnologies Inc. (ADVM) has a current P/FCF of -0.30. The 5-year average P/FCF is -2.39. The thresholds are as follows: Strongly Undervalued below -8.57, Undervalued between -8.57 and -5.48, Fairly Valued between 0.71 and -5.48, Overvalued between 0.71 and 3.80, and Strongly Overvalued above 3.80. The current Forward P/FCF of -0.30 falls within the Historic Trend Line -Fairly Valued range.

Adverum Biotechnologies Inc (ADVM) has a current Price-to-Book (P/B) ratio of -2.97. Compared to its 3-year average P/B ratio of 0.94 , the current P/B ratio is approximately -416.08% higher. Relative to its 5-year average P/B ratio of 1.09, the current P/B ratio is about -371.40% higher. Adverum Biotechnologies Inc (ADVM) has a Forward Free Cash Flow (FCF) yield of approximately -226.29%. Compared to its 3-year average FCF yield of -107.33%, the current FCF yield is approximately 110.84% lower. Relative to its 5-year average FCF yield of -84.62% , the current FCF yield is about 167.41% lower.

-2.97

P/B

Median3y

0.94

Median5y

1.09

-226.29

FCF Yield

Median3y

-107.33

Median5y

-84.62

Competitors Valuation Multiple

The average P/S ratio for ADVM's competitors is 10.68, providing a benchmark for relative valuation. Adverum Biotechnologies Inc Corp (ADVM) exhibits a P/S ratio of 4.59, which is -57.01% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

ADVM.O

Adverum Biotechnologies Inc

Werewolf Therapeutics Inc

Plus Therapeutics Inc

Performance Decomposition

Market capitalization of ADVM increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of ADVM in the past 1 year is driven by Unknown.